The A.S.H.
sent an update on haemostasis today:
 |
Romiplostim Improves Platelet Counts, Chemotherapy Adherence in Patients With Chemotherapy-Induced Thrombocytopenia Patients with solid tumor cancers were able to continue treatment with chemotherapy with fewer delays and dose reductions, though efficacy was less robust in patients with lymphoid malignancies. |
 |
Registry Analysis Finds Off-Label Rituximab Improves Outcomes in Patients With iTTP In subgroup analyses, the authors also noted that Caucasian patients with relapsed iTTP had significantly longer relapse-free survival, compared with African American patients. |
 |
Romiplostim and Eltrombopag Beat Rituximab for Secondline Chronic Immune Thrombocytopenia Treatment The two FDA-approved thrombopoietin receptor agonists were associated with lower risks of complications for patients whose disease failed to respond to corticosteroids. |
No comments:
Post a Comment